Accumulating experimental and clinical evidences over the last decade indicate that GLP-1 analogues have a series of central nervous system and peripheral target tissues actions which are able to significantly influence the liver metabolism. GLP-1 analogues pleiotropic effects proved to be efficacious in T2DM subjects not only reducing liver steatosis and ameliorating NAFLD and NASH, but also in lowering plasma glucose and liver inflammation, improving cardiac function and protecting from kidney dysfunction. While the experimental and clinical data are robust, the precise mechanisms of action potentially involved in these protective multi-target effects need further investigation. Here we present a systematic review of the most recent literature data on the multi-target effects of GLP-1 analogues on the liver, on adipose and muscular tissue and on the nervous system, all capable of influencing significant aspects of the fatty liver disease physiopathology. From this analysis, we can conclude that the multi-target beneficial action of the GLP-1 analogues could explain the positive effects observed in animal and human models on progression of NAFLD to NASH.

Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) / F. Bifari, R. Manfrini, M.V. DEI CAS, C. Berra, M. Siano, M. Zuin, R.C. Paroni, F. Folli. - In: PHARMACOLOGICAL RESEARCH. - ISSN 1043-6618. - 137(2018 Nov), pp. 219-229. [10.1016/j.phrs.2018.09.025]

Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

F. Bifari
Writing – Original Draft Preparation
;
M.V. DEI CAS
Data Curation
;
M. Siano
Data Curation
;
M. Zuin
Data Curation
;
R.C. Paroni
Writing – Original Draft Preparation
;
F. Folli
Writing – Original Draft Preparation
2018

Abstract

Accumulating experimental and clinical evidences over the last decade indicate that GLP-1 analogues have a series of central nervous system and peripheral target tissues actions which are able to significantly influence the liver metabolism. GLP-1 analogues pleiotropic effects proved to be efficacious in T2DM subjects not only reducing liver steatosis and ameliorating NAFLD and NASH, but also in lowering plasma glucose and liver inflammation, improving cardiac function and protecting from kidney dysfunction. While the experimental and clinical data are robust, the precise mechanisms of action potentially involved in these protective multi-target effects need further investigation. Here we present a systematic review of the most recent literature data on the multi-target effects of GLP-1 analogues on the liver, on adipose and muscular tissue and on the nervous system, all capable of influencing significant aspects of the fatty liver disease physiopathology. From this analysis, we can conclude that the multi-target beneficial action of the GLP-1 analogues could explain the positive effects observed in animal and human models on progression of NAFLD to NASH.
GLP1 receptor agonists; NASH; NAFLD; Insulin resistance; Obesity; Metabolic syndrome; Diabetes
Settore MED/09 - Medicina Interna
nov-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
pagination_YPHRS_4012.pdf

accesso riservato

Descrizione: Graphical abstract, articolo principale, e supplementary materials
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 2.24 MB
Formato Adobe PDF
2.24 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
1-s2.0-S1043661818311071-main-1.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.64 MB
Formato Adobe PDF
1.64 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/596677
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 50
social impact